Potential for BioXmark liquid fiducial marker to improve identification of superficial component of canine oral tumors for computer-based radiation therapy planning.

Benoit Clerc-Renaud, Mary-Keara Boss, Lynn R Griffin, Susan M LaRue, Del Leary

Abstract read

In one paragraph

Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

BioXmark® liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial.Clinical and translational radiation oncology · 2023
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benoit Clerc-RenaudDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Mary-Keara BossDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Lynn R GriffinDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Susan M LaRueDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Del LearyDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to evaluate a novel liquid fiducial marker, BioXmark, to improve identification of the superficial component of oral tumors in dogs with computed tomography imaging. Liquid fiducial marker was injected in 6 patients at the visible and palpable extent of each tumor. Gross tumor volumes with and without BioXmark were compared in terms of volume and conformity using a Paddick conformity index, Dice similarity coefficient, and gross tumor volumes mismatch analysis. All patients showed an increase in gross tumor volumes defined by BioXmark compared with the conventionally identified post-contrast gross tumor volumes contours. Volumetric conformity and gross tumor volumes mismatch analysis of the superficial component of gross tumor volumes resulted in a median conformity index of 0.61 and median Dice similarity coefficient of 0.76. The superficial gross tumor volumes showed a median increase of 47% when BioXmark was used. This study demonstrated a potential utility to combining liquid fiducial markers to post-contrast computed tomography images for improved oral tumor localization and gross tumor volumes contouring for radiation therapy planning.

Indexed as

AnimalsComputersDog DiseasesDogsFiducial MarkersMouth NeoplasmsRadiotherapy, Image-GuidedTomography, X-Ray Computed

Identifiers

PMID31597992

PMCPMC6741831

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.